Zian Pan

Mr. Zian Pan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XWXuan Wang
Xuan Wang
YLYunhao Li
Yunhao Li
FJFan Jia
Fan Jia
XCXinyue Cui
Xinyue Cui
ZPZian Pan
Zian Pan
YWYan Wu
Yan Wu
Background: By hindering energy supply pathway for cancer cells, an alternative therapeutic strategy modality is put forward: tumor starvation therapy. And yet only in this blockade of glucose supply which is far from enough to result in sheer apoptosis of cancer cells. Results: In an effort to boost nutrient starvation-dominated cancer therapy, here a novel mitochondrial Ca2+ modulator Alg@CaP were tailor-made for the immobilization of Glucose oxidase for depriving the intra-tumoral glucose, followed by the loading of Curcumin to augment mitochondrial Ca2+ overload to maximize the therapeutic efficiency of cancer starvation therapy via mitochondrial dysfunctions. Also, autophagy inhibitors Obatoclax were synchronously incorporated in this nano-modulator to highlight autophagy inhibition. Conclusion: Here, a promising complementary modality for the trebling additive efficacy of starvation therapy was described for cutting off the existing energy sources in starvation therapy through Curcumin-augmented mitochondrial Ca2+ overload and Obatoclax-mediated autophagy inhibition. Graphical

2 March 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YGYujuan Gao
Yujuan Gao
YLYunhao Li
Yunhao Li
ZPZian Pan
Zian Pan
CXChenlu Xu
Chenlu Xu
XZXiaoyu Zhang
Xiaoyu Zhang
YWYan Wu
Yan Wu

27 March 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
FJFan Jia
Fan Jia
YLYunhao Li
Yunhao Li
YGYujuan Gao
Yujuan Gao
XWXuan Wang
Xuan Wang
JLJianqing Lu
Jianqing Lu
YWYan Wu
Yan Wu

24 April 2023 in Nanomaterials
Verified
Journal Article
Open access
PDF file
YLYunhao Li
Yunhao Li
YGYujuan Gao
Yujuan Gao
ZPZian Pan
Zian Pan
FJFan Jia
Fan Jia
CXChenlu Xu
Chenlu Xu
YWYan Wu
Yan Wu
Breast cancer is a common malignant tumor among women and has a higher risk of early recurrence, distant metastasis, and poor prognosis. Systemic chemotherapy is still the most widely used treatment for patients with breast cancer. However, unavoidable side effects and acquired resistance severely limit the efficacy of treatment. The multi-drug combination strategy has been identified as an effective tumor therapy pattern. In this investigation, we demonstrated a triple collaboration strategy of incorporating the chemotherapeutic drug doxorubicin (DOX) and anti-angiogenesis agent combretastatin A4 (CA4) into poly(lactic-co-glycolic acid) (PLGA)-based co-delivery nanohybrids (PLGA/DC NPs) via an improved double emulsion technology, and then a polydopamine (PDA) was modified on the PLGA/DC NPs’ surface through the self-assembly method for photothermal therapy. In the drug-loaded PDA co-delivery nanohybrids (PDA@PLGA/DC NPs), DOX and CA4 synergistically induced tumor cell apoptosis by interfering with DNA replication and inhibiting tumor angiogenesis, respectively. The controlled release of DOX and CA4-loaded PDA@PLGA NPs in the tumor region was pH dependent and triggered by the hyperthermia generated via laser irradiation. Both in vitro and in vivo studies demonstrated that PDA@PLGA/DC NPs enhanced cytotoxicity under laser irradiation, and combined therapeutic effects were obtained when DOX, CA4, and PDA were integrated into a single nanoplatform. Taken together, the present study demonstrates a nanoplatform for combined DOX, CA4, and photothermal therapy, providing a potentially promising strategy for the synergistic treatment of breast cancer.